

(<http://aphanet.org>)

[Home](#) > Agent receives second FDA approval to refractory or relapsed large B-cell lymphoma

Generic Name:

Tisagenlecleucel

Trade Name:

Kymriah

Company:

Novartis

Notes:

FDA has approved [tisagenlecleucel suspension](#) for I.V. infusion for its second indication? treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. It is not indicated for treatment of patients with primary central nervous system lymphoma.

The agent was the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in August 2017 to treat patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

Tisagenlecleucel is now the only CAR-T cell therapy to receive FDA approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B-cell ALL

Medication Monitor Categories:

[Supplemental Approvals](#)

Source URL: <http://aphanet.org/supplemental-approvals/agent-receives-second-fda-approval-refractory-or-relapsed-large-b-cell>